Skip to main content
Journal ArticleOPEN ACCESS

New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Clinical Case Reports (2021) 9(1) 61-66
DOI: 10.1002/ccr3.3418
9Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.

Author supplied keywords

Cite

CITATION STYLE

APA

Guida, A., Perri, F., Ionna, F., Ascierto, P. A., & Grimaldi, A. M. (2021). New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. Clinical Case Reports, 9(1), 61–66. https://doi.org/10.1002/ccr3.3418

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free